Pathophysiology of pulmonary function anomalies in COVID-19 survivors

Pierantonio Laveneziana, Lucile Sesé, Thomas Gille
Breathe 2021 17: 210065; DOI: 10.1183/20734735.0065-2021

Abstract

Coronavirus disease 2019 (COVID-19) is a disease caused by a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-​2), and the predisposing and protecting factors have not been fully elucidated. COVID-19 primarily impacts the respiratory system, and can result in mild illness or serious disease leading to critical illness requiring admission to the intensive care unit due to respiratory failure. After hospital discharge, the more commonly described pulmonary function anomalies are alterations in diffusing capacity and the loss of lung volume. Reduction of inspiratory muscle contraction may also be underestimated. This article will focus on the pathophysiology of pulmonary function anomalies in COVID-19 survivors. We will discuss current advances and provide future directions and also present our perspective on this field.

Abstract

COVID-19 primarily impacts the respiratory system and can result in long-standing alterations in pulmonary function such as anomalies in diffusing capacity and the loss of lung volume https://bit.ly/3gKDo5e

Introduction

Coronavirus disease 2019 (COVID-19) is a disease caused by a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which primarily impacts the respiratory system. COVID-19 can result in mild illness or serious disease leading to critical illness requiring admission to an intensive care unit (ICU) due to respiratory failure.

There is intense discussion around potential factors predisposing to and protecting from COVID-19. Children and young people have less severe acute COVID-19 than adults. Severe disease was found to be rare and death exceptionally rare in a large prospective cohort study of children admitted to hospital with laboratory confirmed COVID-19 in the UK [1]. Nonetheless, a study based on data from the National Health Interview Survey in the USA has pointed out that nearly 32% of young adults (aged 18–25 years) and half that (16%) for nonsmoking young adults were found to be medically vulnerable to severe COVID-19 illness [2]. A word of caution is mandatory here because these findings in young adults need to be compared with other indicators related to severe COVID-19 illness, such as hospitalisation rates and mortality. Smoking appears to be a key factor that confers medical vulnerability among young adults [2]. The risk of severe COVID-19 outcomes is also consistently lower in women than men worldwide, suggesting protective immunomodulatory and anti-inflammatory actions of high physiological concentrations of the steroids 17β-oestradiol (E2) and progesterone (P4) in women [3]. More research is needed in this area. Another issue is the impact of age ≥65 years and the pre-existing concurrent cardiovascular or cerebrovascular diseases that are deemed to be predictors for high mortality of COVID-19 pneumonia [4].

A major unresolved conundrum is the large spectrum of clinical presentations of patients with COVID-19, ranging from asymptomatic infections or symptomatic mild infections with fever, headache or mild respiratory symptoms (like cough or sore throat) and malaise in 80–85% of patients to flu-like illness and viral pneumonia. Within the “pneumonia phenotype” we also have a large clinical and pathophysiological spectrum that extends from only minor opacification with near normal chest radiographs and mild hypoxaemia (in ∼80% of hospitalised patients). Some of these patients develop an acute respiratory failure with severe hypoxaemia and quick progression to a phenotype presenting with greater hypoxaemia and higher respiratory rates (∼15% of hospitalised patients) to severe disease manifestations. Seriously ill patients develop severe hypoxaemia requiring high-flow oxygen therapy then mechanical ventilation. Their computed tomography (CT) scans document oedema in the lower lobes and multiple ground-glass opacities, angio-CTs may detect micro-embolic lesions and lung ultrasonography that are consistent with interstitial injury with B lines (white lung). This latter phenotype is compatible with either a diffuse alveolar damage or an organising pneumonia with hypoxic vasoconstriction associated with severe hypoxaemia (∼2/3 of patients requiring mechanical ventilation). The last phenotype, less common than the previous one, represents an advanced stage with associated acute lung injury requiring mechanical ventilation [5]. A subset of severe COVID-19 patients also present with coagulation defects with elevated levels of D-dimers and fibrinogen suggesting thrombotic microangiopathy and vasculopathy in the gas-exchange networks and systemically [6–8]. This latter phenotype suggests a combination of respiratory and vascular dysfunction in the lungs of severely ill COVID-19 patients, which was confirmed in several recent pathological studies [9, 10]. The particular feature of SARS-CoV-2 to induce both respiratory and vascular dysfunction has been established in the past year [11, 12].

Increasing evidence suggests that these diverse clinical phenotypes might be explained by an immunological failure to control and restrict SARS-CoV-2 infection of the lung. Failure and skewing of the adaptive immune system, promiscuous infection of epithelial (pneumocytes) and endothelial as well as immune cells, coagulation defects and uncontrolled neutrophilic activation potentially govern the impact of COVID-19 on respiratory function and clinical phenotypes (figure 1) [9, 12–15]. An increased understanding of the respiratory dysfunction underlying the different clinical phenotypes of COVID-19 survivors impacts the management of clinical and pathophysiological consequences of this disease. The pathophysiology of pulmonary function anomalies in COVID-19 survivors will be at the centre of this article. We will discuss current advances and provide future directions and also present our perspective on this field.

Figure 1
Figure 1

Overview of the most common pulmonary pathology findings observed in post-mortem patients affected by various degrees of severity of COVID-19. See the text for more details and explanations.

Physiology and pathophysiology of abnormal pulmonary function variables as observed in COVID-19 survivors

Altered lung diffusion capacity is the most common anomaly followed by restrictive ventilatory defect. This section attempts to describe the physiology and pathophysiology that underlies the three most common abnormal pulmonary function variables observed in COVID-19 survivors: transfer factor of the lung for carbon monoxide (TLCO), TLCO/alveolar volume (VA) and total lung capacity (TLC). A particular focus will be paid to highlighting the difference between TLCO and KCO and on what is important about having a greater decline in TLCO than in KCO, and how this feeds back to lung pathology.

Altered TLCO or DLCO in COVID-19 survivors

The lung transfer (or diffusing) capacity for carbon monoxide (TLCO or DLCO; TLCO being more commonly used in Europe whereas DLCO is more commonly used in North America) reflects the capacity of carbon monoxide transfer from the environment to the pulmonary capillary blood and represents the most clinically practical standard methodology to assess gas exchange in the lung. In this article we will use the term TLCO. KCO, the transfer or diffusion coefficient, is the rate constant for carbon monoxide uptake from alveolar gas and is impacted mostly by the thickness and area of the alveolar capillary membrane, the volume of blood circulating in pulmonary capillaries coupling ventilated alveoli and the concentration and properties of haemoglobin in the alveolar capillaries blood (figure 2). KCO and VA are the two main factors that determine TLCO (figure 2). From a mathematical standpoint, KCO can be calculated as TLCO/VA under BTPS conditions (Body Temperature, ambient Pressure, Saturated with water vapour). It should be noted that KCO is not a simple ratio, as the relationship between lung volume and carbon monoxide uptake is certainly less than 1:1 [16]. The use of KCO has recently been recommended instead of TLCO/VA, as TLCO/VA may be interpreted that TLCO can be normalised for VA [17].

Figure 2
Figure 2

Factors contributing to lung transfer (or diffusing) capacity for carbon monoxide ( TLCO or DLCO). See the text for more details and explanations.

Factors contributing to altered TLCO or DLCO in COVID-19 survivors

A low TLCO is not exclusively determined by reduced VA [18]; residual interstitial anomalies [19–21] and pulmonary vascular anomalies (i.e. abnormal capillary–alveolar units) [22] may play a fundamental role and this could also be the case in COVID-19 survivors (figure 3). This holds true as the interpretation of low TLCO must consider the complex relationship between VA, TLCO and KCO, and may inopportunely exclude the presence of abnormal gas exchange in the lung (figure 3). To prove this point, we can use data from “severe pneumonia” COVID-19 related patients discussed in this review article to model according to Hughes and Pride [16] what TLCO and KCO responses would be expected if VA was diminished as a consequence of either suboptimal alveolar expansion or due to loss of alveolar units while having a normal expansion in communicating alveoli. We would then observe two trajectories:

  • 1) in the first the decline in TLCO would be largely greater than expected if a decrease in VA was the unique anomaly, regardless of the mechanism behind the diminished VA; and

  • 2) the second one is that a decrease in VA due to either of the abovementioned mechanisms would be associated with an augmentation in KCO, which would be contrary to the diminished KCO observed in many of the discharged patients with severe COVID-19; therefore, the decrease in KCO may suggest that loss of alveolar units is not sufficient to determine the observed alteration in TLCO.

Figure 3
Figure 3

Algorithm allowing physiologists and clinicians to unravel mechanisms of a decreased TLCO (or DLCO). If TLCO (or DLCO) is reduced, the next step is to check whether the VA is preserved or reduced. If  VA is diminished, the next step is to check whether the VA/TLC ratio is low (<80%) due to ventilation maldistribution secondary to an obstructive ventilatory defect or is preserved (≥80%) due to restrictive ventilatory defect, associated or not with impaired pulmonary gas exchange. If  VA is preserved, please follow the arrows in the algorithm to get some explanations and to see whether the KCO is reduced and if there are pulmonary gas exchange anomalies associated with this. “Coronavirus diseases” appears in red, as potential mechanisms explaining the TLCO (or DLCO) anomalies observed in coronavirus diseases such as COVID-19 (caused by SARS-CoV-2), severe acute respiratory syndrome (SARS; caused by SARS-CoV-1) and Middle East respiratory syndrome (MERS; caused by MERS-CoV) are yet not fully understood. See the text for more details and explanations. IPF: idiopathic pulmonary fibrosis; ILD: interstitial lung disease.

Altered TLCO or DLCO in COVID-19 survivors: a dangerous interplay between VA and KCO

While the anomalies in TLCO observed in patients affected by “severe pneumonia” COVID-19 may be partially explained by diminished VA, the decrease in KCO measured together with the diminished VA also implies that abnormal gas exchange in the lung occurs (figure 3). Now, the question arises as whether this is due to anomaly of the alveolar–capillary barrier or to abnormal pulmonary blood volume. Unfortunately, this cannot be easily determined based on data presented in the studies discussed in this review article. Lung fibrosis associated with acute respiratory distress syndrome (ARDS) in COVID-19 patients would likely alter alveolar-capillary units, giving rise to loss of alveolar units and altered gas exchange in the lung. The consequence would be a decrease in both VA and KCO (for that diminished VA). There is mounting evidence for impaired pulmonary haemodynamics in COVID-19 patients [10], including vascular pruning, decreased pulmonary blood volume and abnormal pulmonary blood volume distribution as measured via high-resolution CT [23]. Figure 3 shows that a decrease in KCO may develop in the context of alveolar-capillary damage, microvascular pathology, or anaemia. Factors responsible for a reduced VA are numerous and may include decreased alveolar expansion, alveolar damage or loss, or inspired gas maldistribution in the context of an obstructive ventilatory defect. Therefore, when KCO turns normal, in the presence of a low TLCO, it is associated with reduced VA, thus indicating a restrictive ventilatory defect (see below and figure 3). This is because only the functional alveolar units have been sampled thereby providing an erroneous picture toward more preserved areas of the lungs (figure 3). It should be noted that if VA is preserved, there is no restrictive ventilatory defect because VA is always a fraction of TLC, i.e. if VA is preserved so is TLC (figure 3). To conclude and for the sake of clarity: the same TLCO may occur with various combinations of VA and KCO, each suggesting different abnormal respiratory conditions. It is difficult to interpret which one plays the predominant role because both diminished VA and KCO concur to the pathogenesis of altered lung diffusion capacity. TLCO gives a global evaluation of gas exchange in the lung, while the alveolar-capillary membrane diffusing capacity only depends on molecular diffusion of the membranes. We would thus need more refined techniques capable of measuring more specifically the alveolar-capillary membrane. These could include measurement of TLCO with inhaled gas mixtures containing two or three different oxygen fractions, or combined TLCO and transfer (or diffusing) capacity measurements of the lung for nitric oxide (TLNO or DLNO). Such sophisticated analysis could shed light on the precise mechanisms of reduced TLCO in COVID-19 survivors and may allow distinguishing between interstitial and pulmonary capillary anomalies. On this topic, an Italian study by Barisione and Brusasco [24] in 94 patients recovering from mild-to-severe COVID-19 found a greater alteration of TLNO than TLCO, suggesting loss of alveolar units with alveolar membrane damage rather than loss of lung capillary bed (see “Future directions, perspectives and conclusions” section).

Restrictive ventilatory defect in COVID-19 survivors

The second most common abnormality in COVID-19 survivors is a restrictive ventilatory defect. A restrictive ventilatory defect is defined by a pathologically decreased TLC. If caused by parenchymal lung disease, restrictive ventilatory defect is accompanied by reduced gas transfer, which may be marked clinically by desaturation during exercise or even at rest (see the above paragraph).

Factors contributing to restrictive ventilatory defect in COVID-19 survivors

TLC is the greatest volume of gas in the lungs achieved after maximal voluntary inspiration. It depends on the static balance between the outward forces generated by inspiratory muscles during a maximal inspiratory effort and the inward elastic forces of the chest wall and lung. It is the lung that normally contributes the most to the elastic recoil forces of the respiratory system at TLC. At TLC, these two sets of forces are equal and opposite in sign. The decrease in TLC usually reflects the reduced lung volumes either because of an alteration in lung parenchyma or because of a disease of the pleura, chest wall, or neuromuscular apparatus that may respectively affect the compliance of the lung or the compliance of the chest wall or the pressure-generating capacity of the inspiratory muscles. Interstitial lung anomalies, such as those observed in some forms of COVID-19 [25], may result in a restrictive ventilatory defect (figures 1 and 3).

Abnormal respiratory function in COVID-19 patients

Respiratory function testing has been performed in COVID-19 survivors at the time of hospital discharge and weeks after hospital discharge. This seems an important issue when dealing with COVID-19 survivors as these respiratory function testing anomalies may have a huge impact on the management, independence and quality of life of these patients as well as on healthcare systems.

At the time of hospital discharge

In the study by Fumagalli et al. [26], 13 patients with COVID-19 pneumonia were enrolled and the authors found that at the time of clinical recovery, 10 out of 13 patients presented with a restrictive pattern measured by spirometry: forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) were lower than lower limit of normality values, while FEV1/FVC was higher compared with the upper limit of normality values. These results obtained in a very small sample size should be taken with caution as measurement of TLC, preferably with plethysmography, was not included and the diagnosis of restrictive pattern was made exclusively on the reduced FVC, which is questionable and not acceptable [27]. In addition, TLCO measurement was not employed; this would have permitted a better understanding of the origin and the quality of pulmonary gas exchange damage.

In the study by Mo et al. [20], 110 patients with COVID-19 infection were enrolled, which included 24 cases of mild illness, 67 cases of pneumonia and 19 cases of severe pneumonia. Spirometry, plethysmography and TLCO tests were performed on the day of or 1 day before hospital discharge. The authors found that 47% of their patients had anomalies in TLCO, 25% in TLC, 14% in FEV1, 9% in FVC, 4.5% in the FEV1/FVC ratio and 7% in small airway function. The most interesting observation was the significant difference in impaired TLCO among the different groups of severity, which accounted for 30% in mild illness, 42% in pneumonia and 84% in severe pneumonia, respectively (p<0.05). This trend of the gradual decrease in level of TLCO among patients was identical with the varying degree of severity. Of note, in 50% of the TLCO-impaired patients, KCO was still within the normal range, which might indicate that the TLCO decrease was more than the KCO in recovered subjects. In addition, the value of TLC as % of predicted in severe pneumonia cases was much less than that of pneumonia or mild illness, suggesting higher impairment of lung volume in severe cases. No significant difference among the discharged survivors with different severity with regards to other ventilatory defects (e.g. reduced FEV1/FVC) was observed.

These two studies, strongly suggest that respiratory function needs to be carefully investigated in COVID-19 patients, as was already done for other atypical pneumonias such as severe influenza A (H1N1) pneumonia [28]. This is because the lung is the most affected organ in COVID-19 and previous other atypical pneumonias, with anomalies that include diffuse alveolar epithelium destruction, capillary damage/bleeding, hyaline membrane formation, alveolar septal fibrous proliferation, and pulmonary consolidation.

In discharged patients

In the same study by Fumagalli et al. [26], FVC was still lower than the lower limit of normality after 6 weeks from hospital discharge. Again, these results obtained in a very small sample size should be taken with caution as measurement of TLC was not included and the diagnosis of restrictive pattern was made exclusively on the reduced FVC, which is questionable and not acceptable [27]. Another study by Huang et al. [29] performed respiratory function testing in 57 COVID-19 patients after 30 days following hospital discharge and found anomalies in 75% of them; 10%, 9%, 44%, 12% and 53% of enrolled patients had FVC, FEV1, FEV1/FVC ratio, TLC, and TLCO values <80% of predicted values, respectively, whereas 49% and 23% of patients presented with maximum static inspiratory and expiratory pressure (PImax and PEmax, respectively) values <80% of the corresponding predicted values. Compared with non-severe cases (n=40), severe patients (n=17) showed higher incidence of TLCO impairment (76% versus 43%, p=0.019), and significantly lower percentage of predicted TLC. Of note, only 11% of patients showed obstructive and 12% restrictive ventilatory defects [29]. What is also striking, yet surprising, is that a small percentage of patients with no residual imaging abnormalities presented with a slight decrease in TLCO. Similar to this study, Frija-Masson et al. [30] observed abnormal lung function in more than 50% of COVID-19 patients after 30 days from hospital discharge. One third of the abovementioned patients had decreased TLCO values indicating that these patients have lung vascular damage, which coincides with the data from Huang et al. [29].

By constrast, Rogliani et al. [31] have recently pointed out that hospitalised patients with mild-to-moderate forms of COVID-19 are not at risk of developing pulmonary fibrosis. In their study, patients were enrolled within 2 months from hospital discharge and the authors found that FEV1 and FVC, both expressed as % predicted, were in the normal range. Again, these results should be taken with caution as neither measurement of TLC nor of TLCO was included in the study.

Several studies have explored pulmonary function in COVID-19 survivors at 3 months [21, 32–35] and 4 months [36–38] after hospital discharge. Most of these studies showed alteration in TLCO (in more than 50% of patients), in TLC (in more than 10% of patients), and in pressure-generating capacity of respiratory muscles (in less than 40–50% of patients), but to a much lesser extent alterations in the airway functions (in less than 10% of patients). However, the proportion of altered lung function may be lower in studies that included patients with less severe initial disease [39, 40]. Taken together, these studies strongly converged to the conclusion that the worse the lung involvement during SARS-CoV-2 infection (in those patients who developed ARDS or those who required invasive mechanical ventilation) the worse the impairment in pulmonary function after 3–6 months, especially in terms of TLCO, and the lower the likelihood to normalise pulmonary function over time. Accordingly, respiratory rehabilitation and gradual physical activity immediately after hospital discharge should be encouraged as it can minimise impairment or improve respiratory function such as TLC and TLCO, quality of life and anxiety in these fragile patients [41].

In conclusion, several mechanisms, sequential or not, may occur and explain the damages induced by SARS-CoV-2 infections of the lungs. They include the microvascular damage with interstitial thickening with clear lungs on radiology examinations along with a severe hypoxaemia [42, 43], the development of alveolar injury inducing a gradual loss of the alveolar spaces [43], and last but not least the diminished VA that may be explained by changes in mechanical properties of the lungs and the chest wall and by dysfunction of the respiratory muscles after critical illness. These anomalies can be temporary or responsible for a potential long-lasting pulmonary parenchymal dysfunction post-COVID-19 [44].

Potential hypotheses on altered TLCO or DLCO in COVID-19 survivors

Given the interplays discussed above, two hypotheses on reduced TLCO can be proposed in COVID-19 survivors: 1) a reduced TLCO with normal KCO may be in favour of definitive alveolar loss/destruction, with no optimistic perspectives of recovering; 2) a reduced TLCO with diminished KCO may be in favour of alveolar lesions (pulmonary capillary and/or membrane anomalies) that are still evolving, with the optimistic perspective of some and at least partial recovery. We should therefore follow-up COVID-19 survivors to see whether they are able to recover from their TLCO anomalies. Few studies have explored “predictors” for lung function decline, especially for TLCO. Pulmonary interstitial damage (inferred by the chest CT total severity score), the development of acute respiratory distress syndrome, and vascular damage (inferred by high D-dimer levels at the time of hospital admission) have been pointed out as potential predictors for lung function decline, especially for TLCO but also for TLC [21, 22].

Specific features of respiratory dysfunction in COVID-19 compared with other viral pneumonias (SARS, MERS, and influenza A H1N1)

The observations of anomalies in respiratory function, especially in TLCO, in more than 50% of the COVID-19 survivors raises the question of a potential progression towards lung fibrosis in some patients. Interestingly, the greater decline in TLCO compared with KCO suggests that impaired diffusion across the membrane may be more causative for pulmonary dysfunction than reduced lung volume. Previous studies have demonstrated that patients that recovered from coronavirus pneumonia still have damaged lungs. Impaired lung function was common and lasted for months or even years. In follow-up studies on rehabilitating SARS patients lasting from 6 months to 3 years, impaired TLCO was the most common anomaly, ranging from 15% to 44%, followed by reduced TLC, ranging from 5% to 11% [45–47]. Park et al. [48] showed that 37% of MERS survivors still presented with an impairment of TLCO, but normal TLC at 12 months. In addition, pulmonary function improved significantly in the first 3 months but with no further significant improvement from 3 to 6 months after discharge among survivors of severe influenza A (H1N1) pneumonia [28]. Some other studies showed a complete normalisation of pulmonary function 6 months after H1N1-related ARDS [49]. However, about 80% of survivors of ARDS not provoked by influenza A H1N1 had reduced diffusing capacity, 20% had airway obstruction, and 20% had a restrictive pattern 12 months after recovery [50]. These data are discordant with preliminary follow-up results on COVID-19 survivors highlighting the greater and persistent decline of pulmonary function (TLCO and TLC) in COVID-19 survivors compared with SARS, MERS, and influenza A (H1N1) survivors.

Studies on lung function in COVID-19 survivors at 6 and 12 months from hospital discharge are thus urgently needed in order to monitor the long-term effect of COVID-19 infection on the respiratory system in patients with severe-to-extremely-severe pneumonia. A prediction would be that, at least at 6 months from hospital discharge, these patients may still present with an abnormal TLCO and, to lesser extent, a restrictive ventilatory defect. Indeed, a Chinese study by Huang et al. [51], conducted at 6 months after hospital discharge, found a TLCO <80% of predicted value in 33% of patients, and a TLC <80% predicted in 16% of patients. Moreover, studies with serial pulmonary function testing would be essential to better assess functional trajectories.

Future directions, perspectives and conclusions

Physiological understanding of early as well as chronic lung responses might be helpful for future stratification of surviving COVID-19 patients with chronic respiratory impairment. In our opinion, potential future directions and perspectives are as follows.

  • Pathological and lung function evidence for a vascular component among severe COVID-19 patients, which has long-lasting consequences, should be explored.

  • Pathophysiological evidence on deranged adaptive immune function that may drive fibrotic lung diseases and evidence for impaired diffusion capacity in survivors of severe COVID-19 needs to be evaluated.

  • More attention should be paid to COVID-19 survivors presenting with impaired (minor or not) diffusion capacity and perhaps with persistent dyspnoea but with no other associated anomalies in chest or CT scan imaging. Techniques capable of measuring more specifically the alveolar–capillary membrane, such as measurement of TLCO including inhaled gas mixtures containing two or three different oxygen fractions or combined TLCO and TLNO measurements, are welcome to shed light on the precise mechanisms of reduced TLCO in COVID-19 survivors particularly in distinguishing between interstitial and pulmonary capillary anomalies.

  • More particularly, two hypotheses on reduced TLCO could be tested in COVID-19 survivors: 1) a reduced TLCO with normal KCO may be in favour of definitive alveolar loss/destruction, with no optimistic perspectives of recovering; 2) a reduced TLCO with diminished KCO may be in favour of alveolar lesions (pulmonary capillary and/or membrane anomalies) that are still evolving, with potential and optimistic perspective of some recovery, at least in part. We should therefore follow-up COVID-19 survivors to see whether they are able to recover from their TLCO anomalies.

  • A long-lasting follow-up in terms of respiratory function testing is proposed for COVID-19 survivors as results from literature are conflicting as to whether these patients may fully recover or even develop pulmonary sequelae.

This perspective on physiological abnormalities might foster a better understanding of the disease course and may also shape future stratification of patients and treatment options.

Footnotes

  • Conflict of interest: P. Laveneziana reports personal fees from Chiesi France, Boehringer Ingelheim France, and Novartis France, outside the submitted work.

  • Conflict of interest: L. Sesé reports personal fees from Boehringer Ingelheim, Roche and AstraZeneca, and other (congress registration) from Oxyvie (oxygen provider), AstraZeneca and Novartis, outside the submitted work.

  • Conflict of interest: T. Gille reports personal fees from Boehringer Ingelheim and Roche, other (congress registration) from Oxyvie (oxygen provider), LVL Medical (oxygen provider) and Vitalaire (oxygen provider), outside the submitted work.

  • Received April 27, 2021.
  • Accepted June 14, 2021.
http://creativecommons.org/licenses/by-nc/4.0/

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Swann OV,
    2. Holden KA,
    3. Turtle L, et al.
    Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ 2020; 370: m3249. doi:10.1136/bmj.m3249
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Adams SH,
    2. Park MJ,
    3. Schaub JP Jr., et al.
    Medical vulnerability of young adults to severe COVID-19 illness-data from the national health interview survey. J Adolesc Health 2020; 67: 362–368. doi:10.1016/j.jadohealth.2020.06.025
    OpenUrl
  3. ↵
    1. Mauvais-Jarvis F,
    2. Klein SL,
    3. Levin ER
    . Estradiol, progesterone, immunomodulation, and COVID-19 outcomes. Endocrinology 2020; 161: bqaa127. doi:10.1210/endocr/bqaa127
    OpenUrlPubMed
  4. ↵
    1. Du RH,
    2. Liang LR,
    3. Yang CQ, et al.
    Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 2020; 55: 2000524.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Rello J,
    2. Storti E,
    3. Belliato M, et al.
    Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J 2020; 55: 2001028. doi:10.1183/13993003.01028-2020
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Huertas A,
    2. Montani D,
    3. Savale L, et al.
    Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? Eur Respir J 2020; 56: 2001634. doi:10.1183/13993003.01634-2020
    OpenUrlAbstract/FREE Full Text
    1. Iba T,
    2. Connors JM,
    3. Levy JH
    . The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res 2020; 69: 1181–1189. doi:10.1007/s00011-020-01401-6
    OpenUrlPubMed
  8. ↵
    1. Vinayagam S,
    2. Sattu K
    . SARS-CoV-2 and coagulation disorders in different organs. Life Sci 2020; 260: 118431. doi:10.1016/j.lfs.2020.118431
    OpenUrlCrossRefPubMed
  9. ↵
    1. Ackermann M,
    2. Verleden SE,
    3. Kuehnel M, et al.
    Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med 2020; 383: 120–128. doi:10.1056/NEJMoa2015432
    OpenUrlCrossRefPubMed
  10. ↵
    1. Potus F,
    2. Mai V,
    3. Lebret M, et al.
    Novel insights on the pulmonary vascular consequences of COVID-19. Am J Physiol Lung Cell Mol Physiol 2020; 319: L277–L288. doi:10.1152/ajplung.00195.2020
    OpenUrl
  11. ↵
    1. Varga Z,
    2. Flammer AJ,
    3. Steiger P, et al.
    Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417–1418. doi:10.1016/S0140-6736(20)30937-5
    OpenUrlCrossRefPubMed
  12. ↵
    1. Del Turco S,
    2. Vianello A,
    3. Ragusa R, et al.
    COVID-19
    and cardiovascular consequences: is the endothelial dysfunction the hardest challenge?     Thromb Res 2020; 196: 143–151. doi:10.1016/j.thromres.2020.08.039
    OpenUrl
    1. Tay MZ,
    2. Poh CM,
    3. Renia L, et al.
    The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020; 20: 363–374. doi:10.1038/s41577-020-0311-8
    OpenUrlCrossRefPubMed
    1. Gordon DE,
    2. Hiatt J,
    3. Bouhaddou M, et al.
    Comparative host–coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science 2020; 370: 6521. doi:10.1126/science.abe9403
    OpenUrlCrossRef
  15. ↵
    1. Casadevall A,
    2. Pirofski LA
    . In fatal COVID-19, the immune response can control the virus but kill the patient. Proc Natl Acad Sci USA 2020: 117: 30009–30011. doi:10.1073/pnas.2021128117
    OpenUrlFREE Full Text
  16. ↵
    1. Hughes JM,
    2. Pride NB
    . Examination of the carbon monoxide diffusing capacity (DLCO) in relation to its KCO and
    VA components    . Am J Respir Crit Care Med 2012; 186: 132–139. doi:10.1164/rccm.201112-2160CI
    OpenUrlCrossRefPubMed
  17. ↵
    1. Graham BL,
    2. Brusasco V,
    3. Burgos F, et al.
    2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J 2017; 49: 1600016. doi:10.1183/13993003.00016-2016
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Nusair S
    . Abnormal carbon monoxide diffusion capacity in COVID-19 patients at time of hospital discharge. Eur Respir J 2020; 56: 2001832. doi:10.1183/13993003.01832-2020
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Chen R,
    2. Gao Y,
    3. Chen M, et al.
    Impaired pulmonary function in discharged patients with COVID-19: more work ahead. Eur Respir J 2020; 56: 2002194. doi:10.1183/13993003.02194-2020
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Mo X,
    2. Jian W,
    3. Su Z, et al.
    Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J 2020; 55: 2001217. doi:10.1183/13993003.01217-2020
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Qin W,
    2. Chen S,
    3. Zhang Y, et al.
    Diffusion capacity abnormalities for carbon monoxide in patients with
    COVID-19 at 3-month follow-up    . Eur Respir J 2021; 58: 2003677.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Morris MF,
    2. Pershad Y,
    3. Kang P, et al.
    Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease. Eur Respir J 2021; in press [https://doi.org/10.1183/13993003.04133-2020].
  23. ↵
    1. Lins M,
    2. Vandevenne J,
    3. Thillai M, et al.
    Assessment of small pulmonary blood vessels in COVID-19 patients using HRCT. Acad Radiol 2020; 27: 1449–1455. doi:10.1016/j.acra.2020.07.019
    OpenUrl
  24. ↵
    1. Barisione G,
    2. Brusasco V
    . Lung diffusing capacity for nitric oxide and carbon monoxide following mild-to-severe COVID-19. Physiol Rep 2021; 9: e14748. doi:10.14814/phy2.14748
    OpenUrl
  25. ↵
    1. Polak SB,
    2. Van Gool IC,
    3. Cohen D, et al.
    A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol 2020; 33: 2128–2138. doi:10.1038/s41379-020-0603-3
    OpenUrl
  26. ↵
    1. Fumagalli A,
    2. Misuraca C,
    3. Bianchi A, et al.
    Pulmonary function in patients surviving to COVID-19 pneumonia. Infection 2021; 49: 153–157. doi:10.1007/s15010-020-01474-9
    OpenUrl
  27. ↵
    1. Pellegrino R,
    2. Viegi G,
    3. Brusasco V, et al.
    Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948–968. doi:10.1183/09031936.05.00035205
    OpenUrlFREE Full Text
  28. ↵
    1. Hsieh MJ,
    2. Lee WC,
    3. Cho HY, et al.
    Recovery of pulmonary functions, exercise capacity, and quality of life after pulmonary rehabilitation in survivors of ARDS due to severe influenza A (H1N1) pneumonitis. Influenza Other Respir Viruses 2018; 12: 643–648. doi:10.1111/irv.12566
    OpenUrlCrossRefPubMed
  29. ↵
    1. Huang Y,
    2. Tan C,
    3. Wu J, et al.
    Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res 2020; 21: 163. doi:10.1186/s12931-020-01429-6
    OpenUrlCrossRefPubMed
  30. ↵
    1. Frija-Masson J,
    2. Debray MP,
    3. Gilbert M, et al.
    Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection. Eur Respir J 2020; 56: 2001754. doi:10.1183/13993003.01754-2020
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Rogliani P,
    2. Calzetta L,
    3. Coppola A, et al.
    Are there pulmonary sequelae in patients recovering from COVID-19? Respir Res 2020; 21: 286. doi:10.1186/s12931-020-01550-6
    OpenUrl
  32. ↵
    1. Cortes-Telles A,
    2. Lopez-Romero S,
    3. Figueroa-Hurtado E, et al.
    Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnoea. Respir Physiol Neurobiol 2021; 288: 103644. doi:10.1016/j.resp.2021.103644
    OpenUrl
    1. Shah AS,
    2. Wong AW,
    3. Hague CJ, et al.
    A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax 2021; 76: 402–404. doi:10.1136/thoraxjnl-2020-216308
    OpenUrlAbstract/FREE Full Text
    1. Frija-Masson J,
    2. Bancal C,
    3. Plantier L, et al.
    Alteration of diffusion capacity after SARS-CoV-2 infection: a pathophysiological approach. Front Physiol 2021; 12: 624062. doi:10.3389/fphys.2021.624062
    OpenUrl
  35. ↵
    1. Froidure A,
    2. Mahsouli A,
    3. Liistro G, et al.
    Integrative respiratory follow-up of severe COVID-19 reveals common functional and lung imaging sequelae. Respir Med 2021; 181: 106383. doi:10.1016/j.rmed.2021.106383
    OpenUrl
  36. ↵
    1. Anastasio F,
    2. Barbuto S,
    3. Scarnecchia E, et al.
    Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life. Eur Respir J 2021; in press [https://doi.org/10.1183/13993003.04015-2020].
    1. Bellan M,
    2. Soddu D,
    3. Balbo PE, et al.
    Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. JAMA Netw Open 2021; 4: e2036142. doi:10.1001/jamanetworkopen.2020.36142
    OpenUrlCrossRef
  38. ↵
    1. Guler SA,
    2. Ebner L,
    3. Aubry-Beigelman C, et al.
    Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J 2021; 57; 2003690. doi:10.1183/13993003.03690-2020
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Lerum TV,
    2. Aaløkken TM,
    3. Brønstad E, et al.
    Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19. Eur Respir J 2021; 57: 2003448. doi:10.1183/13993003.03448-2020
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Zhao YM,
    2. Shang YM,
    3. Song WB, et al.
    Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine 2020; 25: 100463. doi:10.1016/j.eclinm.2020.100463
    OpenUrl
  41. ↵
    1. Liu K,
    2. Zhang W,
    3. Yang Y, et al.
    Respiratory rehabilitation in elderly patients with COVID-19: a randomized controlled study. Complement Ther Clin Pract 2020; 39: 101166. doi:10.1016/j.ctcp.2020.101166
    OpenUrlPubMed
  42. ↵
    1. McGonagle D,
    2. O'Donnell JS,
    3. Sharif K, et al.
    Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2020; 2: e437–e445. doi:10.1016/S2665-9913(20)30121-1
    OpenUrl
  43. ↵
    1. Tian S,
    2. Hu W,
    3. Niu L, et al.
    Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol 2020; 15: 700–704. doi:10.1016/j.jtho.2020.02.010
    OpenUrlCrossRefPubMed
  44. ↵
    1. Spagnolo P,
    2. Balestro E,
    3. Aliberti S, et al.
    Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med 2020; 8: 750–752. doi:10.1016/S2213-2600(20)30222-8
    OpenUrl
  45. ↵
    1. Hui DS,
    2. Joynt GM,
    3. Wong KT, et al.
    Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax 2005; 60: 401–409. doi:10.1136/thx.2004.030205
    OpenUrlAbstract/FREE Full Text
    1. Hui DS,
    2. Wong KT,
    3. Ko FW, et al.
    The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors. Chest 2005; 128: 2247–2261. doi:10.1378/chest.128.4.2247
    OpenUrlCrossRefPubMed
  47. ↵
    1. Ngai JC,
    2. Ko FW,
    3. Ng SS, et al.
    The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology 2010; 15: 543–550. doi:10.1111/j.1440-1843.2010.01720.x
    OpenUrlCrossRefPubMed
  48. ↵
    1. Park WB,
    2. Jun KI,
    3. Kim G, et al.
    Correlation between pneumonia severity and pulmonary complications in Middle East respiratory syndrome. J Korean Med Sci 2018; 33: e169. doi:10.3346/jkms.2018.33.e169
    OpenUrl
  49. ↵
    1. Toufen C Jr.,
    2. Costa EL,
    3. Hirota AS, et al.
    Follow-up after acute respiratory distress syndrome caused by influenza a (H1N1) virus infection. Clinics (Sao Paulo) 2011; 66: 933–937. doi:10.1590/S1807-59322011000600002
    OpenUrlCrossRef
  50. ↵
    1. Orme J Jr.,
    2. Romney JS,
    3. Hopkins RO, et al.
    Pulmonary function and health-related quality of life in survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med 2003; 167: 690–694. doi:10.1164/rccm.200206-542OC
    OpenUrlCrossRefPubMed
  51. ↵
    1. Huang C,
    2. Huang L,
    3. Wang Y, et al.
    6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 220–232. doi:10.1016/S0140-6736(20)32656-8
    OpenUrlCrossRefPubMed
Back to top
Email
Print
Alerts
Citation Tools

Pathophysiology of pulmonary function anomalies in COVID-19 survivors
Pierantonio Laveneziana, Lucile Sesé, Thomas Gille
Breathe Sep 2021, 17 (3) 210065; DOI: 10.1183/20734735.0065-2021
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

Subjects